Literature DB >> 16775270

Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations.

S J Hayflick1, M Hartman, J Coryell, J Gitschier, H Rowley.   

Abstract

BACKGROUND AND
OBJECTIVE: Patients with a clinical diagnosis of neurodegeneration with brain iron accumulation (NBIA, formerly called Hallervorden-Spatz syndrome) often have mutations in PANK2, the gene encoding pantothenate kinase 2. We investigated correlations between brain MR imaging changes, mutation status, and clinical disease features.
METHODS: Brain MRIs from patients with NBIA were reviewed by 2 neuroradiologists for technical factors, including signal intensity abnormalities in specific brain regions, presence and location of atrophy, presence of white matter abnormality, contrast enhancement, and other comments. PANK2 genotyping was performed by polymerase chain reaction amplification of patient genomic DNA followed by automated nucleotide sequencing.
RESULTS: Sixty-six MR imaging examinations from 49 NBIA patients were analyzed, including those from 29 patients with mutations in PANK2. All patients with mutations had the specific pattern of globus pallidus central hyperintensity with surrounding hypointensity on T2-weighted images, known as the eye-of-the-tiger sign. This sign was not seen in any studies from patients without mutations. Even before the globus pallidus hypointensity developed, patients with mutations could be distinguished by the presence of isolated globus pallidus hyperintensity on T2-weighted images. Radiographic evidence for iron deposition in the substantia nigra was absent early in disease associated with PANK2 mutations. MR imaging abnormalities outside the globus pallidus, including cerebral or cerebellar atrophy, were more common and more severe in mutation-negative patients. No specific MR imaging changes could be distinguished among the mutation-negative patients.
CONCLUSION: MR imaging signal intensity abnormalities in the globus pallidus can distinguish patients with mutations in PANK2 from those lacking a mutation, even in the early stages of disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775270      PMCID: PMC2099458     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  6 in total

1.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome.

Authors:  B Zhou; S K Westaway; B Levinson; M A Johnson; J Gitschier; S J Hayflick
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

2.  MR imaging in a case of Hallervorden-Spatz disease.

Authors:  G Tanfani; M Mascalchi; G C Dal Pozzo; N Taverni; A Saia; C Trevisan
Journal:  J Comput Assist Tomogr       Date:  1987 Nov-Dec       Impact factor: 1.826

3.  Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations.

Authors:  K D Sethi; R J Adams; D W Loring; T el Gammal
Journal:  Ann Neurol       Date:  1988-11       Impact factor: 10.422

4.  Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome.

Authors:  S J Hayflick; J M Penzien; W Michl; U M Sharif; N P Rosman; P G Wheeler
Journal:  Pediatr Neurol       Date:  2001-08       Impact factor: 3.372

Review 5.  Hallervorden-Spatz syndrome and brain iron metabolism.

Authors:  K F Swaiman
Journal:  Arch Neurol       Date:  1991-12

6.  Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.

Authors:  Susan J Hayflick; Shawn K Westaway; Barbara Levinson; Bing Zhou; Monique A Johnson; Katherine H L Ching; Jane Gitschier
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

  6 in total
  46 in total

1.  Conversion disorder as initial diagnosis in pantothenate kinase associated neurodegeneration.

Authors:  I Vansteenkiste; W A van Gool; D J Hofstee; Marina A J Tijssen
Journal:  J Neurol       Date:  2010-08-18       Impact factor: 4.849

2.  'Eye-of-the-tiger' sign and classic pantothenate kinase associated neurodegeneration.

Authors:  Mahesh Kamate; Rajendra Mali; Vinayak Tonne; Shivanand Bubanale
Journal:  Indian J Pediatr       Date:  2010-09-30       Impact factor: 1.967

3.  Dementia and movement disorders.

Authors:  D Dormont; D J Seidenwurm
Journal:  AJNR Am J Neuroradiol       Date:  2008-01       Impact factor: 3.825

Review 4.  The neuropathology of neurodegeneration with brain iron accumulation.

Authors:  Michael C Kruer
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

5.  Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation.

Authors:  L Timmermann; K A M Pauls; K Wieland; R Jech; G Kurlemann; N Sharma; S S Gill; C A Haenggeli; S J Hayflick; P Hogarth; K L Leenders; P Limousin; C J Malanga; E Moro; J L Ostrem; F J Revilla; P Santens; A Schnitzler; S Tisch; F Valldeoriola; J Vesper; J Volkmann; D Woitalla; S Peker
Journal:  Brain       Date:  2010-03-05       Impact factor: 13.501

Review 6.  Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Authors:  James D Weisfeld-Adams; Ilana B Katz Sand; Justin M Honce; Fred D Lublin
Journal:  Brain       Date:  2015-01-29       Impact factor: 13.501

7.  Panthotenate Kinase-Associated Neurodegeneration Has a Founder Mutation (c.215_216insa) in Indian Agrawal Patients.

Authors:  Vrajesh Udani; Soma Das; Rahul Chhabria
Journal:  Mov Disord Clin Pract       Date:  2016-04-05

Review 8.  Diagnosis of dystonic syndromes--a new eight-question approach.

Authors:  Kelly L Bertram; David R Williams
Journal:  Nat Rev Neurol       Date:  2012-03-20       Impact factor: 42.937

9.  Looking Deep into the Eye-of-the-Tiger in Pantothenate Kinase-Associated Neurodegeneration.

Authors:  J-H Lee; A Gregory; P Hogarth; C Rogers; S J Hayflick
Journal:  AJNR Am J Neuroradiol       Date:  2018-01-25       Impact factor: 3.825

Review 10.  Neurodegeneration with Brain Iron Accumulation.

Authors:  Susanne A Schneider
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.